Annual and transition report of foreign private issuers pursuant to Section 13 or 15(d)

Consolidated Statements of Comprehensive Loss

v3.24.1.1.u2
Consolidated Statements of Comprehensive Loss - USD ($)
 12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Dec. 31, 2021
Expenses      
Research and development $ 2,418,715 $ 6,761,818 $ 677,576
Consulting, wages and benefits 1,037,558 885,460 804,047
Directors' fees 179,406 122,572 49,366
Investor relations 919,490 928,424 412,079
Professional fees 514,263 454,071 226,374
General and administrative 375,505 448,824 139,983
Public company costs 170,184 120,813 188,642
Travel 170,187 22,538 1,849
Amortization of property and equipment 73,062 41,069  
Amortization of intangible assets 66,632 17,077 14,266
Share-based payments 120,984 487,940 396,423
Loss before other items (6,045,986) (10,290,606) (2,910,605)
Fair value adjustment on derivative warrant liability 3,641,403 3,396,137 2,636,391
Foreign exchange loss (7,025) (1,546) (12,373)
Interest income (expense) 253,543 103,589 (4,451)
Transaction costs on derivative warrant liability   (926,456) (1,288,236)
Net loss for the year (2,158,065) (7,718,882) (1,579,274)
Items that may be subsequently reclassified to profit or loss:      
Currency translation differences   (128,145) 150,464
Total comprehensive loss for the year $ (2,158,065) $ (7,847,027) $ (1,428,810)
Basic and diluted loss per common share      
Basic loss per common share $ (1.09) $ (5.22) $ (1.44)
Diluted loss per common share $ (1.09) $ (5.22) $ (1.44)
Weighted average number of common shares outstanding      
Weighted average number of common shares outstanding, Basic 1,981,734 1,479,914 1,094,182
Weighted average number of common shares outstanding, Diluted 1,981,734 1,479,914 1,094,182